MAGCELL® MICROCIRC can positively influence symptoms of neurotoxicities like sensory ataxia, neuropathy and neuropathic pain symptoms (especially CIPN I-IV) on hands and feet as a result of chemotherapy. Moreover a significant increase in nerve conductivity speed (ulnar nerve) was achieved by the treatment.
- Electrode-free electrotherapy for therapists and patients
- Pulsating electromagnetic fields (PEMF)
- Field strength more than 1000 gauss
- Effective treatment concept due to repeatable short-treatment periods
- Through-textile treatment (even through shoes)
- Very easy one-button operation
- Optical and acoustic function control
- Automatic switch-off at the end of the therapy period
Blood flow stimulation
MAGCELL® MICROCIRC significantly increases micro-circulation (p < 0,001) while nitric oxide (NO) has a blood vessel dilatory effect. The authors recommend the therapy for clinical situations where an improvement in micro circulation is identified, like for instance in the case of chronic tissue repair.
(First photo – without magcell microcirc | Second Photo – 2 minutes after treatement. )
MAGCELL® is a portable hand device for electrode-free electrotherapy. Magnetic alternating fields are produced over rotation by permanent magnets. A sinusoidal pulsating electromagnetic field (PEMF) is generated over the special magnet arrangement and device function principle. However, with a value of 0,105 tesla field strength it is many times higher than for commercially available magnetic field therapy devices with coils or mats, which generally operate with field strengths of maximum 100 gauss or 0.01 tesla. By contrast MAGCELL®-therapy units produce field strengths, which are generally stronger by factor 10 than these devices.
According to induction law induced time-variable magnetic fields induce electric fields. The physical effects of MAGCELL® derive from the electric fields produced in living cells and tissue based on induction law. Depending on tissue conductivity the field incites an electric current. Taking into account the specific conductivity for various body tissue and liquids, this electric current can be calculated. Its strength, or more precisely, current density (= current strength per area, A/m²) determines biological effectiveness.
All calculated current densities exceed 10 mA/m² and are thus within the range of effects internationally confirmed and classified as ‘good‘: above the ‘subtle biological effects‘ and within the range of ‘confirmed macro effects‘ (10-100 mA/m²). Induced current densities are much higher again in blood and body fluids. The term ‘electrode-free electrotherapy‘ for MAGCELL® derives from the distinctly strong induced current densities and exceeding of the threshold value of 10 mA/m²: both of which are not found on equipment using coils or mats.
Body fluids (e.g. joint fluid) play a key role in the relevant therapy indications for MAGCELL® devices. The cells in this fluid or adjacent tissue are exposed to the established current densities. MAGCELL® exceeds by far the recognised effective current densities so that treatment is effective even at a tissue depth of 3-5 cm. MAGCELL® also induces above-threshold current densities in the blood, which are crucial for clinical therapy effects, for instance in respect of blood flow stimulation and immunomodulatory processes. The same applies for interstitial liquids, which moreover are found in virtually all organs and tissue. In bones and fatty tissue with low conductivity current densities are well below the effectiveness threshold of 10 mA/m², so a therapeutic effect in this tissue can scarcely be envisaged.
The following effects of electrode-free electrotherapy with MAGCELL® are clinically recorded:
- pain alleviation and movement stimulation e.g. in the case of osteoarthritis
- substantial improvement in circulation
- reduction of sensory neurotoxicities (polyneuropath
Further clinical effects
A dog‘s prostate gland serves as animal model in the case of irregularities in the growth of the human prostate. In a study (Leoci et al. 2014) benign prostatic hyperplasia (BPH) symptoms improved significantly in respect of prostate volume reduction without influencing semen quality, testosterone behaviour or the libido.
Another clinical and experimental study (Funk et al. 2014) confirms that MAGCELL® MICROCIRC also significantly boosts micro-circulation even widens the blood vessels. The authors recommend the therapy for clinical situations where an improvement in micro circulation is identified, like for instance in the case of chronic tissue repair.
Funk H.W., Knels L., Augstein A., Marquetant R., Dertinger H.F. (2014): Potent Stimulation of Blood Flow of Volunteers after Local Short-Term Treatment with Low-Frequency Magnetic Fields from a Novel Device. Evidence-Based Complementary and Alternative Medicine 2014. Article ID 543564, 9 pages. http://dx.doi.org/10.1155/2014/543564.
Geiger G., Mikus E., Dertinger H., Rick O. (2015): Low frequency magnetic field therapy in patients with cytostatic-induced polyneuropathy: A phase II pilot study. Bioelectromagnetics 36(3): 251-254. doi: 10.1002/bem.21897.
Hitrov N.A., Portnov V.V. (2008): MAGCELL® ARTHRO in der Behandlung von Arthrose im Kniegelenk. Die Naturheilkunde 3, 25-27.
Leoci R., Aiudi G., Silvestre F., Lissner E., Lacalandra G.M. (2014): Effect of Pulsed Electromagnetic Field Therapy on Prostate Volume and Vascularity in the Traetment of Benign Prostatic Hyperplasia: A Pilot Study in a Canine Model. The Prostate 74: 1132-1141.
Reimschüssel A., Bodenburg P. (2009): Niederfrequente elektromagnetische Felder. Erfolgreich in der Therapie der Myoarthritis des Kiefergelenkes. Die Naturheilkunde 5, 28.
Rick O., von Hehn U., Mikus E., Dertinger H., Geiger G. (2017): Magnetic Field Therapy in Patients With Cytostatics-Induced Polyneuropathy: A Prospective Randomized Placebo-Controlled Phase-III Study. Bioelectromagnetics 38(2): 85-94:. doi: 10.1002/bem.22005.
Wuschech H., von Hehn U., Mikus E., Funk R.H. (2015): Effects of PEMF on patients with osteoarthritis: Results of a prospective, placebo-controlled, double-blind study. Bioelectromagnetics 36(8), 576–585.